Publication:
Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.

dc.contributor.authorMartín-Martín, Clara
dc.contributor.authorRuiz-Rico, María
dc.contributor.authorBarat, José Manuel
dc.contributor.authorGarcía-Ríos, Estéfani
dc.contributor.authorPérez-Romero, Pilar
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAgencia Estatal de Investigación (España)
dc.contributor.funderGeneralitat Valenciana (España)
dc.contributor.funderUniversity of Notre Dame
dc.date.accessioned2026-06-30T20:06:36Z
dc.date.available2026-06-30T20:06:36Z
dc.date.issued2026-03
dc.description.abstractHuman cytomegalovirus (HCMV) poses serious health risks, particularly for immunocompromised individuals. However, the current FDA-approved anti-HCMV drugs face challenges such as drug resistance and significant side effects, underscoring the need for alternative treatment options. Essential oil components (EOCs), including eugenol, thymol and vanillin, are recognized for their therapeutic potential. This study evaluates their antiviral effects against HCMV in epithelial (ARPE-19) and fibroblast (MRC-5) cell lines. Among the EOCs, vanillin demonstrated the highest efficacy, characterized by low toxicity and a high selectivity index in both cell types. Mechanistic differences were noted between the cell lines. In ARPE-19 cells, eugenol showed virucidal activity, inhibited viral entry and suppressed early gene expression (IE-1). Conversely, in MRC-5 cells, eugenol mainly blocked viral entry and exhibited virucidal effects. Thymol was most effective in ARPE-19 cells, where it completely suppressed IE-1 expression as a result of both inhibition of viral entry and a direct disruptive effect on IE-1 expression. In addition, thymol showed an effect on viral replication. In MRC-5 cells, thymol primarily inhibited viral entry and attachment. Vanillin exhibited dual inhibitory activity in both cell lines, blocking viral attachment and entry. In MRC-5, vanillin also appears to affect intermediate processes. Notably, combining EOCs with ganciclovir resulted in synergistic effects. The eugenol/ganciclovir combination was particularly effective in ARPE-19 cells, while thymol/ganciclovir showed enhanced efficacy in MRC-5 cells. These findings suggest that EOCs have significant potential as adjunct therapies to improve antiviral outcomes and address drug-resistant HCMV strains.
dc.description.peerreviewed
dc.description.sponsorshipThis study was supported by the Spanish Ministry of Science, Innovation and University, Instituto de Salud Carlos III Grant/Award Numbers: PI20CIII-00009 (MPY303/20) and PID2021-128141OB-C21 funded by MCIN/AEI/10.13039/501100011033, by 'ERDF A way of making Europe' and by the Start-up Research Grant University Notre Dame. C.M.-M. is supported by the PFIS Program (FI22CIII/0029), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades. E.G.-R. was supported by the Generalitat Valenciana plan GenT grant no. CIDEIG/2022/028.
dc.format.number3
dc.format.page002248
dc.format.volume107
dc.identifier.citationMartín-Martín C, Ruiz-Rico M, Barat JM, García-Ríos E, Pérez-Romero P. Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection. J Gen Virol. 2026 Mar;107(3):002248. doi: 10.1099/jgv.0.002248. PMID: 41849209; PMCID: PMC12999277.
dc.identifier.doi10.1099/jgv.0.002248
dc.identifier.journalJournal of General Virology
dc.identifier.pubmedID41849209
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27579
dc.language.isoeng
dc.publisherMicrobiology Society
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI 2020/PI20CIII%2F00009/ES/Caracterización de la respuesta inmune de anticuerpos en pacientes con trasplante para el diseño de una vacuna/
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-128141OB-C21/ES/APLICACION DE MATERIALES FUNCIONALIZADOS CON ACTIVIDAD ANTIVIRICA, ANTIBIOFILM, ANIENZIMATICA Y ANTIMICROBIANA EN LA INDUSTRIA ALIMENTARIA/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII//FI22CIII%2F0029/ES//
dc.relation.projectIDinfo:eu-repo/grantAgreement/Generalitat Valenciana/plan GenT/CIDEIG%2F2022%2F028/ES//
dc.relation.publisherversionhttps://doi.org/10.1099/jgv.0.002248
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAntiviral treatment
dc.subjectEugenol
dc.subjectHuman cytomegalovirus
dc.subjectThymol
dc.subjectVanillin
dc.subjectViral infection and dissemination
dc.subject.meshAntiviral Agents
dc.subject.meshBenzaldehydes
dc.subject.meshCell Line
dc.subject.meshCytomegalovirus Infections
dc.subject.meshCytomegalovirus
dc.subject.meshEpithelial Cells
dc.subject.meshEugenol
dc.subject.meshFibroblasts
dc.subject.meshHumans
dc.subject.meshThymol
dc.subject.meshVirus Internalization
dc.subject.meshVirus Replication
dc.titleDecoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationa1288d49-5ff8-4e1b-ae56-1a46945b94ef
relation.isAuthorOfPublication.latestForDiscoverya1288d49-5ff8-4e1b-ae56-1a46945b94ef
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication54733407-1d78-4c44-bf4c-8c8a7592aa4b
relation.isFunderOfPublication842e6617-7822-4501-a927-7e8cedda4aa6
relation.isFunderOfPublicationff8a7a14-d84a-487a-bf80-f968c0ac36b2
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication620794b5-bfea-4aaf-9993-35c681ba12cd
relation.isPublisherOfPublication.latestForDiscovery620794b5-bfea-4aaf-9993-35c681ba12cd

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
DecodingAntiviralPotentialEugenol_2026.pdf
Size:
5.01 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_DecodingAntiviralPotentialEugenol_2026.pdf
Size:
592.99 KB
Format:
Adobe Portable Document Format